Skip to main content

Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Abstract

The introduction of selective cyclooxygenase-2 inhibitors offered the promise of similar efficacy in pain control without the gastrointestinal effects associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs). By blocking prostacyclin formation but leaving platelet-derived thromboxane A2 generation unopposed, there is concern that the potential gastrointestinal benefit of cyclooxygenase-2-selective inhibitors may come at the cost of increased thrombotic risk. However, the differential effects of coxibs on blood pressure, endothelial function, oxidative stress, tissue factor expression, vascular smooth muscle proliferation and neointimal hyperplasia indicate a distinct heterogeneity among this class of drugs. Importantly, the observation of an excess cardiovascular risk with traditional NSAIDs in randomized clinical trials, meta-analysis and large-scale observational studies further highlights the need to scrutinize the entire class of anti-inflammatory drugs, including traditional NSAIDs, as rigorously as coxibs.

Keywords: NSAID; coxib; cyclooxygenase; inflammation; nitric oxide

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1445-5994.2006.01056.x

Affiliations: CardioVascular Center Cardiology, University Hospital Zurich, Zurich, Switzerland

Publication date: May 1, 2006

bsc/imj/2006/00000036/00000005/art00009
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more